Residual enzymatic activity of the tetanus toxin light chain present in tetanus toxoid batches used for vaccine production

Vaccine

Volumn 26, Issue 31, 2008, Pages 3835-3841

  Behrensdorf Nicol, H A ^a   Kegel, B ^a   Bonifas, U ^a   Silberbach, K ^a   Klimek, J ^a   Weisser K ^a   Kramer B ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Residual proteolytic activity; Synaptobrevin; Tetanus toxoid

Indexed keywords

FORMALDEHYDE; NEUROTOXIN; PROTEINASE; SYNAPTOBREVIN; TETANUS ANTIBODY; TETANUS TOXIN; TETANUS TOXOID;

ARTICLE; DRUG MANUFACTURE; ENZYME ACTIVITY; PRIORITY JOURNAL;

ANIMALS; BLOTTING, WESTERN; PEPTIDE HYDROLASES; SPECTROPHOTOMETRY; TETANUS TOXIN; TETANUS TOXOID;

EID: 46149104356     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.014     Document Type: Article

References (40)

1. Link E., Edelmann L., Chou J.H., Binz T., Yamasaki S., Eisel U., et al. Tetanus toxin action: inhibition of neurotransmitter release linked to synaptobrevin proteolysis. Biochem Biophys Res Commun 189 2 (1992) 1017-1023
2. Schiavo G., Benfenati F., Poulain B., Rossetto O., Polverino de Laureto P., DasGupta B.R., et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359 6398 (1992) 832-835
3. Schiavo G., Poulain B., Rossetto O., Benfenati F., Tauc L., and Montecucco C. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J 11 10 (1992) 3577-3583
4. Gill D.M. Bacterial toxins: a table of lethal amounts. Microbiol Rev 46 1 (1982) 86-94
5. Brüggemann H., Bäumer S., Fricke W.F., Wiezer A., Liesegang H., Decker I., et al. The genome sequence of Clostridium tetani, the causative agent of tetanus disease. Proc Natl Acad Sci U S A 100 3 (2003) 1316-1321
6. World Health Organization (WHO). WHO vaccine-preventable diseases: monitoring system, 2006 global summary. WHO document no. WHO/IVB/2006. Geneva, WHO; 2006.
7. Glenny A.T., and Hopkins B.E. Diphtheria toxoid as an immunising agent. Brit J Exp Pathol 4 (1923) 283-288
8. Ramon G. Sur la toxine et sur l'anatoxine diphthériques. Ann Inst Pasteur 38 (1924) 1-10
9. Corbel M.J. Reasons for instability of bacterial vaccines. Dev Biol Stand 87 (1996) 113-124
10. Rappuoli R., and Pizza M. Toxin-based vaccines (diphtheria, tetanus, pertussis). Handbook Exp Pharmacol 133 (1999) 201-224
11. Fowler S., Byron O., Jumel K., Xing D., Corbel M.J., and Bolgiano B. Novel configurations of high molecular weight species of the pertussis toxin vaccine component. Vaccine 21 19-20 (2003) 2678-2688
12. Bolgiano B., Fowler S., Turner K., Sesardic D., Xing D.K.L., Crane D.T., et al. Monitoring of diphtheria, pertussis and tetanus toxoids by circular dichroism, fluorescence spectroscopy and size-exclusion chromatography. Dev Biol (Basel) 103 (2000) 51-59
13. Rait V.K., O'Leary T.J., and Mason J.T. Modeling formalin fixation and antigen retrieval with bovine pancreatic ribonuclease A: I-structural and functional alterations. Lab Invest 84 3 (2004) 292-299
14. Mason J.T., and O'Leary T.J. Effects of formaldehyde fixation on protein secondary structure: a calorimetric and infrared spectroscopic investigation. J Histochem Cytochem 39 2 (1991) 225-229
15. Paliwal R., and London E. Comparison of the conformation, hydrophobicity, and model membrane interactions of diphtheria toxin to those of formaldehyde-treated toxin (diphtheria toxoid): formaldehyde stabilization of the native conformation inhibits changes that allow membrane insertion. Biochemistry 35 7 (1996) 2374-2379
16. Yuen C.-T., Canthaboo C., Menzies J.A., Cyr T., Whitehouse L.W., Jones C., et al. Detection of residual pertussis toxin in vaccines using a modified ribosylation assay. Vaccine 21 1-2 (2002) 44-52
17. Gomez S.R., Yuen C.-T., Asokanathan C., Douglas-Bardsley A., Corbel M.J., Coote J.G., et al. ADP-ribosylation activity in pertussis vaccines and its relationship to the in vivo histamine-sensitisation test. Vaccine 25 17 (2007) 3311-3318
18. Kegel B., Bonifas U., Silberbach K., Krämer B., and Weißer K. In vitro determination of specific toxicity in tetanus vaccines. Dev Biol (Basel) 111 (2002) 27-33
19. Kegel B., Behrensdorf-Nicol H.A., Bonifas U., Silberbach K., Klimek J., Krämer B., et al. An in vitro assay for detection of tetanus neurotoxin activity: using antibodies for recognizing the proteolytically generated cleavage product. Toxicol In Vitro 21 8 (2007) 1641-1649
20. Tetanus vaccine (adsorbed), monograph 0452. In: European Pharmacopoeia, 6th ed. Strasbourg, France: Council of Europe; 2008.
21. Tetanus vaccine for veterinary use, monograph 01/2008:0697. In: European Pharmacopoeia, 6th ed. Strasbourg, France: Council of Europe; 2008.
22. 2+-binding domain of clostridial neurotoxins restore exocytosis in chromaffin cells treated with tetanus or botulinum A neurotoxin. J Biol Chem 269 11 (1994) 8122-8127
23. Caccin P., Rossetto O., Rigoni M., Johnson E., Schiavo G., and Montecucco C. VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes. FEBS Lett 542 1-3 (2003) 132-136
24. Metz B., Jiskoot W., Mekkes D., Kingma R., Hennink W.E., Crommelin D.J.A., et al. Quality control of routine, experimental and real-time aged diphtheria toxoids by in vitro analytical techniques. Vaccine 25 39-40 (2007) 6863-6871
25. Thaysen-Andersen M., Jorgensen S.B., Wilhelmsen E.S., Petersen J.W., and Hojrup P. Investigation of the detoxification mechanism of formaldehyde-treated tetanus toxin. Vaccine 25 12 (2007) 2213-2227
26. Leung T., Corran P.H., Gee C., Ekong T.A.N., and Sesardic D. Application of an in vitro endopeptidase assay for detection of residual toxin activity in tetanus toxoids. Dev Biol (Basel) 111 (2002) 327-332
27. Cryz Jr. S.J., Friedman R.L., Pavlovskis O.R., and Iglewski B.H. Effect of formalin toxoiding on Pseudomonas aeruginosa toxin A: biological, chemical, and immunochemical studies. Infect Immun 32 2 (1981) 759-768
28. Gordon V.M., Whipp S.C., Moon H.W., O'Brien A.D., and Samuel J.E. An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for edema disease of swine. Infect Immun 60 2 (1992) 485-490
29. Rappuoli R., Douce G., Dougan G., and Pizza M. Genetic detoxification of bacterial toxins: a new approach to vaccine development. Int Arch Allergy Immunol 108 4 (1995) 327-333
30. Schiavo G., Papini E., Genna G., and Montecucco C. An intact interchain disulfide bond is required for the neurotoxicity of tetanus toxin. Infect Immun 58 12 (1990) 4136-4141
31. Sesardic D., Corran P.H., Gee C., and Ekong T.A.N. In vitro approaches for estimating activity of tetanus toxin as an alternative assay for specific toxicity. In: Balls M., van Zeller A.-M., and Halder M.E. (Eds). Progress in the reduction, refinement and replacement of animal experimentation (2000), Elsevier, Amsterdam 969-974
32. Ekong T.A.N., Feavers E.M., and Sesardic D. Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Microbiology 143 (1997) 3337-3347
33. Jones R.G., Ochiai M., Liu Y., Ekong T., and Sesardic D. Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. J Immunol Methods 329 1-2 (2008) 92-101
34. Simpson L.L. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 212 1 (1980) 16-21
35. Pearce L.B., Borodic G.E., Johnson E.A., First E.R., and MacCallum R. The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. Toxicon 33 2 (1995) 217-227
36. Botulinum toxin type A for injection, monograph 2113. In: European Pharmacopoeia, 6th ed. Strasbourg, France: Council of Europe; 2008.
37. Corbel M.J., and Xing D.K.L. Toxicity and potency evaluation of pertussis vaccines. Expert Rev Vac 3 1 (2004) 89-101
38. Gomez S.R., Xing D.K.L., Corbel M.J., Coote J., Parton R., and Yuen C.-T. Development of a carbohydrate binding assay for the B-oligomer of pertussis toxin and toxoid. Anal Biochem 356 2 (2006) 244-253
39. Habermann E., and Tayot J.L. Interaction of solid-phase gangliosides with tetanus toxin and toxoid. Toxicon 23 6 (1985) 913-920
40. Robbins J.B., Schneerson R., Keith J.M., Shiloach J., Miller M., and Trollors B. The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP. Vaccine 25 15 (2007) 2811-2816